 |
인쇄하기
취소
|
JW to conduct Phase I trial for new anticancer medicine
Published: 2011-05-13 06:57:00
Updated: 2011-05-13 06:57:00
JW Pharmaceutical has recently announced that it will conduct Phase I clinical trial for CWP231A, a candidate anticancer medicine that interrupts biochemical signals to eradicate leukemia stem cells without affecting normal cells, in the United States within this month.
Last month, the company obtained the approval of clinical tests by the U.S. Food and Drug Administration to develop the dru...
Fees
- Email service daily and homepage access.
- $300 per month.
- 5 Email holders per each company.
- Anual contract base.
Copyright Yakup.com All rights reserved.
약업닷컴의 모든 컨텐츠는 저작권법의 보호를 받습니다. 무단 전재⋅복사⋅배포 등을 금합니다.